loading page

Evaluation of low-dose vaginal misoprostol in pregnancy terminations below 34 weeks of gestation: Time to change the dose?
  • +6
  • TUGBA SARAC SIVRIKOZ,
  • Omer Demir,
  • Savci Telek,
  • Onur Tengilimoglu,
  • Helin Celik,
  • Sule Birol Ince,
  • Eylem Yogurtcuoglu,
  • Ibrahim Kalelioglu,
  • Recep Has
TUGBA SARAC SIVRIKOZ
Istanbul University Istanbul Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Omer Demir
Karadeniz Technical University Faculty of Medicine
Author Profile
Savci Telek
Istanbul University Istanbul Faculty of Medicine
Author Profile
Onur Tengilimoglu
Istanbul University Istanbul Faculty of Medicine
Author Profile
Helin Celik
Istanbul University Istanbul Faculty of Medicine
Author Profile
Sule Birol Ince
Istanbul University Istanbul Faculty of Medicine
Author Profile
Eylem Yogurtcuoglu
Istanbul University Istanbul Faculty of Medicine
Author Profile
Ibrahim Kalelioglu
Istanbul University Istanbul Faculty of Medicine
Author Profile
Recep Has
Istanbul University Istanbul Faculty of Medicine
Author Profile

Abstract

Objective: To evaluate of the effectiveness of low-dose (LD) vaginal misoprostol administration, where dose adjustment was made by taking into account the gestational week and cesarean section (C/S) history in termination of pregnacy (ToP). Design: Retrospective observational cohort study. Setting: A single tertiary center Population: 563 patients who opted ToP under 34 weeks of gestation. Methods: Outcomes were ascertained by health record review and compared between subgroups according to gestational weeks and previous C/S history. Main Outcome Measures: Total misoprostol administration time, total labor time, total misoprostol dose, >1 ToP method, uterin rupture, uterine atony Results: 63% (357) of 563 cases with pregnancy termination were below the 24th gestational week (Gx). The remaining 206 cases (Gy) (37%) were between 24 and 34 weeks of gestation. The rate of C/S history was statistically significantly higher in Gx (p=0.030). While a single termination method below 24 weeks was sufficient in 94% of cases, this rate remained at 86% in Gy (p=0.002). There was no difference in the complication rate between the groups according to the gestational week or the presence of a prior C/S (p>0.05). Concusions: The present regimen is an effective method with low maternal morbidity and high success without increasing the total treatment time. Especially in patients with a history of C/S where the ‘experience of ToP with misoprostol’ have relatively high risk , and in all ToPs below 34 weeks, achieving a high birth rate without increasing the uterine rupture rate suggests that it is a safe approach.